Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lack Of Funding Has "Hobbled" FDA Postmarketing Drug Safety Work – IoM

This article was originally published in The Pink Sheet Daily

Executive Summary

Substantially increased resources are needed to improve FDA's drug safety activities and implement IoM recommendations, report says.

You may also be interested in...



BIO Helps Launch Coalition To Increase FDA Funding, Reduce User Fees Reliance

The Coalition for a Stronger FDA will lobby the administration before shifting its focus to congressional appropriators.

BIO Helps Launch Coalition To Increase FDA Funding, Reduce User Fees Reliance

The Coalition for a Stronger FDA will lobby the administration before shifting its focus to congressional appropriators.

Sweeping Changes At CDER Recommended In IoM Drug Safety Report

Among solutions suggested is six-year fixed term for the FDA commissioner and appointment of external advisory board to oversee cultural changes.

Topics

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel